AKTS
Aktis Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.06
+0.80%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$15.29
From 52W high−53.27%
Volume108889.00
Market cap$837.63M
P/E (TTM)—
P/S (TTM)83.3x
Div yield—
Key dataNov 4, 2026
Open
$15.29
From 52W high
−53.27%
Volume
108889.00
Market cap
$837.63M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.3x
P/E (TTM)
—
RSI (14)
32.8
MomentumView details →
1D Return
+0.80%
YTD Return
—
Similar companies
Latest newsMore news →
Aktis Oncology initiated the Phase 1b BActinium-2 clinical trial of AKY-2519 in patients with non-small cell lung cancer and other B7-H3 expressing solid tumors.34d agoAktis Oncology reported Q2 2026 collaboration revenue of $3.4 million, up from $1.6 million a year earlier, with a net loss of $24.1 million and cash and marketable securities of $517.3 million as of June 30, 2026.84d ago